A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus

Chronic hepatitis B virus (HBV) infection is a global problem. The loss of hepatitis B surface antigen (HBsAg) in serum is a therapeutic end point. Prolonged therapy with nucleoside/nucleotide analogues targeting the HBV-polymerase may lead to resistance and rarely results in the loss of HBsAg. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiruthika, S., Bhat, Ruchika, Dash, Rozaleen, Rathore, Anurag S., Vivekanandan, Perumal, Jayaram, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175705/
https://www.ncbi.nlm.nih.gov/pubmed/34083665
http://dx.doi.org/10.1038/s41598-021-91196-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175705/
https://www.ncbi.nlm.nih.gov/pubmed/34083665
http://dx.doi.org/10.1038/s41598-021-91196-1

Ejemplares similares